Doxycycline for Sexually Transmitted Infection Prevention: Evolving Evidence and Implementation Perspectives

Connie Celum; Anne F Luetkemeyer

doi:10.1097/OLQ.0000000000001501

Doxycycline for Sexually Transmitted Infection Prevention: Evolving Evidence and Implementation Perspectives

Sex Transm Dis. 2021 Sep 1;48(9):620-621. doi: 10.1097/OLQ.0000000000001501.

Authors

Connie Celum¹, Anne F Luetkemeyer²

Affiliations

¹ From the Departments of Global Health, Medicine, and Epidemiology, University of Washington, Seattle, WA.
² Division of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General, University of California San Francisco, San Francisco, CA.

Abstract

Editorial for Sexually Transmitted Diseases (STD20–495): Interest, concerns, and attitudes among men who have sex with men and healthcare providers toward prophylactic use of doxycycline against Chlamydia trachomatis infections and syphilis.

Publication types

Editorial
Comment

MeSH terms

Chlamydia Infections*
Doxycycline / therapeutic use
Humans
Sexually Transmitted Diseases* / epidemiology
Sexually Transmitted Diseases* / prevention & control

Substances

Doxycycline

Grants and funding

R01 AI143439/AI/NIAID NIH HHS/United States